You have the power to give your low-risk patients a chance at superior* outcomes by guiding them to a Heart Team for a TAVR evaluation

The 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease recommends that all patients with symptomatic severe heart disease be evaluated by a Multidisciplinary Heart Valve Team when intervention is considered.1 Together you and the Heart Team can create a personalized, guideline-based treatment pathway that is right for your patients.

* The PARTNER 3 TRIAL, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehabilitation and multiple pre-specified secondary endpoints.

Use this tool to find the nearest Heart Team for a TAVR evaluation.

    Recommended resources

    See all resources

    References:   1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020. Epublished DOI: 10.1016/j. jacc.2020.11.018.